

2015

INFORMATION ON JAPANESE REGULATORY AFFAIRS

*Regulatory Information Task Force
Japan Pharmaceutical Manufacturers Association*

**Pharmaceutical
Administration and
Regulations in Japan**

Japan Pharmaceutical Manufacturers Association

2015

<http://www.jpma.or.jp/about/issue/gratis/index2.html> (Japanese)

<http://www.jpma.or.jp/english/parj/whole.html> (English)

Pharmaceutical Administration and Regulations in Japan

This file contains information concerning pharmaceutical administration, regulations, and new drug development in Japan updated annually by the English RA Information Task Force, International Affairs Committee, Japan Pharmaceutical Manufacturers Association (JPMA). The contents are not abstracts of governmental rules or regulations but concise descriptions of most current practices by regulatory agencies and the industry that the working group complies. The file does not contain anything related to forecasts. The file is available also at the homepage of National Institute of Health Sciences (<http://www.nihs.go.jp/kanren/iyaku.html>).

Japan Pharmaceutical Manufacturers Association

<http://www.jpma.or.jp/english/>

Table of Contents

CHAPTER 1..... 1

ORGANIZATION AND FUNCTION OF THE MINISTRY OF HEALTH, LABOUR AND WELFARE..... 1

1. PHARMACEUTICAL AND FOOD SAFETY BUREAU (PFSB) 1
 - 1.1 General Affairs Division 1
 - 1.2 Evaluation and Licensing Division 1
 - 1.3 Safety Division 2
 - 1.4 Compliance and Narcotics Division 2
 - 1.5 Blood and Blood Products Division 2
2. HEALTH POLICY BUREAU 3
 - 2.1 Economic Affairs Division 3
 - 2.2 Research and Development Division 3
3. NATIONAL INSTITUTE OF HEALTH SCIENCES 3
4. PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA), AN INDEPENDENT ADMINISTRATIVE ORGANIZATION 3
 - 4.1 Office of Review Administration 4
 - 4.2 Office of Review Management 4
 - 4.3 Office of Standards and Guidelines Development 4
 - 4.4 Office of International Programs 4
 - 4.5 Office of New Drug I..... 4
 - 4.6 Office of New Drug II..... 4
 - 4.7 Office of New Drug III 4
 - 4.8 Office of New Drug IV..... 4
 - 4.9 Office of New Drug V..... 5
 - 4.10 Office of Cellular and Tissue-based Products 5
 - 4.11 Office of Vaccines and Blood Products 5
 - 4.12 Office of OTC and Generics ... 5
 - 4.13 Office of Generics 5
 - 4.14 Office of Medical Devices I... 5
 - 4.15 Office of Medical Devices II . 5
 - 4.16 Office of Medical Devices III 5
 - 4.17 Office of Compliance and Standards 5
 - 4.18 Office of Safety I..... 5
 - 4.19 Office of Safety II..... 5
 - 4.21 Electronic Data Promotion Group 5
5. THE NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION (INDEPENDENT ADMINISTRATIVE AGENCY) 5
6. PHARMACEUTICAL AFFAIRS AND FOOD SANITATION COUNCIL (PAFSC) .. 5
7. NATIONAL INSTITUTE OF INFECTIOUS DISEASES..... 6

CHAPTER 2..... 11

PHARMACEUTICAL LAWS AND REGULATIONS 11

1. PHARMACEUTICAL LAWS 11
2. DRUGS AND MEDICAL DEVICES LAW 11
3. OUTLINE OF PHARMACEUTICAL REGULATIONS 12
 - 3.1 Definition of Drugs 12
 - 3.2 Definition of Drugs 12
 - 3.3 License for Manufacturing/Marketing Businesses 13
 - 3.4 License for Manufacturing Business and Accreditation of Overseas Manufacturers 14
 - 3.5 Manufacturing/Marketing Approvals 15

- 3.6 Good Manufacturing Practice (GMP) 15
- 3.7 Drug Master File (MF) 15
- 3.8 Drug Retail Seller Licensing ... 15
- 3.9 Quality Standards and Government Certification 16
- 3.10 Labeling and Package Inserts 16
- 3.11 Proper Advertisement 16
- 3.12 Good Laboratory Practice (GLP) 16
- 3.13 Good Clinical Practice (GCP) 16
- 3.14 Good Post-marketing Study Practice (GPSP) 17
- 3.15 Reexamination and Reevaluation 17
- 3.16 Adverse Drug Reaction (ADR) and Infection Reporting 18
- 3.17 Risk Management Plan..... 18
- 3.18 Dissemination of Information 18
- 3.19 Measures related to the Law Concerning Access to Information Held by Administrative Organizations 18
- 3.20 Patent System 19
- 3.21 Drug Abuse Control 19
4. MARKETING APPROVALS 20
 - 4.1 Drug Marketing Approvals 20
 - 4.2 Marketing Approval Reviews .. 20
 - 4.3 Manufacturing/Marketing Approval Application with Electronic Data 21
 - 4.4 Regulatory Strategy Consultations for Regenerative Medicine Products 21
 - 4.5 Approval System Implemented to Promote the Application of Regenerative Medicine Including Cellular and Tissue-Based Products for Commercialization (Approval with Conditions and Time Limit) . 21
 - 4.6 Priority Review System and Designation of Drug Products for Priority Reviews 21
 - 4.7 Restrictive Approval System .. 22
 - 4.8 Orphan Drugs..... 22
 - 4.9 Drugs for Pediatric Use 22
 - 4.10 Unapproved Drugs and Drugs of Off-label Use 23
 - 4.11 Packaging Strategy for World-first Products 23
 - 4.12 Biosimilar Products..... 23
 - 4.13 Combination Products..... 24
 - 4.14 Codevelopment..... 24
 - 4.15 Transfer of Marketing Approvals 24
 - 4.16 Approval Applications for Drugs Manufactured Overseas 24
 - 4.17 Issuing of Certificates for Exported Drugs by MHLW 24
5. JAPANESE PHARMACOPOEIA AND OTHER STANDARDS 25
 - 5.1 Japanese Pharmacopoeia (JP) 25
 - 5.2 Standards Based on Article 42 of the Pharmaceutical Affairs Law . 25
 - 5.3 Standards for Biological Materials 26
 - 5.4 Quality Standards Based on Notifications 26
 - 5.5 Government Batch Test 26
6. PHARMACEUTICAL SUPERVISION 26
 - 6.1 Pharmaceutical Supervision... 26
 - 6.2 Product Recalls 27
 - 6.3 Prevention of Medical Accidents Caused by Drugs, etc. 27
 - 6.4 Safety Measures against Bovine Spongiform Encephalitis (BSE) 27

CHAPTER 3-----35

Drug Development

1. PROCESS FROM DEVELOPMENT TO APPROVAL 35
 - 1.1 Development of New Drugs
 - 1.2 Procedures for Clinical Trials

1.3 Safety information on Adverse Reactions and Infections during the Study	
1.4 Interview advice meetings	
1.5 Approval review	
1.6 Compliance review	
1.7 GMP compliance inspection	
2. DATA REQUIRED FOR APPROVAL APPLICATIONS-----	41
3. GUIDELINES CONCERNING DRUG APPROVAL APPLICATIONS-----	43
4. Other-----	57

CHAPTER 4 -----73

Post-marketing Surveillance of Drugs

1. GVP-----	74
2. GPSP-----	78
3. PAPER COMPLIANCE REVIEW AND ON-SITE GPSP SURVEYS OF DATA FOR REEXAMINATION AND REEVALUATION-----	80
4. ADVERSE DRUG REACTIONS AND INFECTIONS REPORTING SYSTEM-----	80
4.1 Adverse Drug Reaction and Infectious Disease Reporting System by Pharmaceutical Companies	
4.2 Drug and Medical Device Safety Information Reporting System by Medical Personnel	
4.3 WHO International Drug Monitoring Program	
5. PERIODIC INFECTION REPORTS FOR BIOLOGICAL PRODUCTS (ARTICLE 68-14 and 68-24 in THE LAW)-----	82
6. REEXAMINATION SYSTEM (ARTICLE 14-4 AND 23-29 OF THE PHARMACEUTICAL AFFAIRS LAW)---	82
6.1 Designation for Reexamination of Drugs	
6.2 Periodic Safety Reports (Article 63 of the Enforcement Regulations of the Law)	
6.3 Data Required for Reexamination Applications and Reexamination Procedures	
7. REEVALUATION SYSTEM (ARTICLES 14-6 AND 23-31 OF THE LAW) -----	83

CHAPTER 5 -----90

Supply and Dissemination of Drug Safety Management Information

1. PACKAGE INSERTS -----	90
1.1 Guidance on the Style and Format of Package Inserts	
1.2 Headings and Their Sequence in Package Inserts	
1.3 Precautions	
1.4 Labeling of Excipients	
1.5 Entries for Biological Products	
1.6 Brand Names of Prescriptions Drugs	
1.7 Information on Package Inserts in English	
2. INFORMATION TO SUPPLEMENT PACKAGE INSERTS-----	94
2.1 Outline of Prescription Pharmaceutical Product Information	
2.2 Pharmaceutical Interview Forms (IF)	

3. SUPPLY AND DISSEMINATION OF SAFETY MANAGEMENT INFORMATION-----	94
3.1 Distribution of Emergency Safety Information (Yellow Letters)	
3.2 Safety Flash Report (Blue Letters)	
3.3 Distribution of Information by 'Notices of Revision of Precautions'	
3.4 Dissemination of Information for Drugs That Have Completed Reexamination or Reevaluation	
3.5 Dissemination of ADR Information by the Pharmaceuticals and Medical Devices Safety Information (Information on Adverse Reactions to Drugs)	
3.6 Dissemination of Information by Drug Safety Update	
3.7 Commentaries on "Precautions" in Package Inserts of New Drugs	
4. ELECTRONIC INFORMATION DISSEMINATION -----	97
5. PACKAGE INSERTS OF NON-PRESCRIPTION DRUGS -----	98
6. PACKAGE INSERTS OF GUIDANCE-MANDATORY DRUGS-----	98

CHAPTER 6 -----102

Health Insurance Programs and Drug Pricing in Japan

1. HISTORY OF HEALTH INSURANCE PROGRAMS-----	102
2. MEDICAL BENEFITS OFFERED UNDER HEALTH INSURANCE PROGRAMS -----	102
3. REIMBURSEMENT OF MEDICAL FEES ---	103
4. NATIONAL HEALTH INSURANCE PRICE LIST -----	103
5. PRICING FORMULA FOR REIMBURSEMENT PRICE REVISIONS OF DRUGS LISTED IN THE NHI PRICE LIST -----	103
6. RECENT REVISIONS OF THE NHI PRICE LIST -----	104
7. DETERMINATION OF REIMBURSEMENT PRICES FOR NEW DRUGS -----	104
8. ENTRY OF GENERIC DRUGS IN THE NHI PRICE LIST -----	105
9. ISSUES RELATED TO THE USE OF DETERMINATION OF UNAPPROVED DRUGS AND OFF-LABEL USE-----	105